HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms.

Abstract
Alkylphospholipids and alkylphosphocholines (APCs) are promising antitumor agents, which target the plasma membrane and affect multiple signal transduction networks. We investigated the therapeutic potential of erucylphosphohomocholine (ErPC3), the first intravenously applicable APC, in human acute myelogenous leukemia (AML) cells. ErPC3 was tested on AML cell lines, as well as AML primary cells. At short (6-12 h) incubation times, the drug blocked cells in G2/M phase of the cell cycle, whereas, at longer incubation times, it decreased survival and induced cell death by apoptosis. ErPC3 caused JNK 1/2 activation as well as ERK 1/2 dephosphorylation. Pharmacological inhibition of caspase-3 or a JNK 1/2 inhibitor peptide markedly reduced ErPC3 cytotoxicity. Protein phosphatase 2A downregulation by siRNA opposed ERK 1/2 dephosphorylation and blunted the cytotoxic effect of ErPC3. ErPC3 was cytotoxic to AML primary cells and reduced the clonogenic activity of CD34(+) leukemic cells. ErPC3 induced a significant apoptosis in the compartment (CD34(+) CD38(Low/Neg) CD123(+)) enriched in putative leukemia-initiating cells. This conclusion was supported by ErPC3 cytotoxicity on AML blasts showing high aldehyde dehydrogenase activity and on the side population of AML cell lines and blasts. These findings indicate that ErPC3 might be a promising therapeutic agent for the treatment of AML patients.
AuthorsA M Martelli, V Papa, P L Tazzari, F Ricci, C Evangelisti, F Chiarini, C Grimaldi, A Cappellini, G Martinelli, E Ottaviani, P Pagliaro, S Horn, J Bäsecke, L H Lindner, H Eibl, J A McCubrey
JournalLeukemia (Leukemia) Vol. 24 Issue 4 Pg. 687-98 (Apr 2010) ISSN: 1476-5551 [Electronic] England
PMID20200557 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Erucic Acids
  • Phosphoinositide-3 Kinase Inhibitors
  • RNA, Messenger
  • erucylphosphohomocholine ErPC3
  • Phosphorylcholine
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • MAP Kinase Kinase 4
  • Protein Phosphatase 2
Topics
  • Animals
  • Apoptosis (drug effects)
  • Blotting, Western
  • Cell Cycle (drug effects)
  • Cell Proliferation (drug effects)
  • Cells, Cultured
  • Erucic Acids (pharmacology)
  • Flow Cytometry
  • Fluorescent Antibody Technique
  • Humans
  • Immunoenzyme Techniques
  • Leukemia, Myeloid, Acute (drug therapy, metabolism, pathology)
  • MAP Kinase Kinase 4 (metabolism)
  • Mice
  • Mitogen-Activated Protein Kinase 1 (antagonists & inhibitors, metabolism)
  • Mitogen-Activated Protein Kinase 3 (antagonists & inhibitors, metabolism)
  • Phosphatidylinositol 3-Kinases (metabolism)
  • Phosphoinositide-3 Kinase Inhibitors
  • Phosphorylcholine (analogs & derivatives, pharmacology)
  • Precursor Cells, B-Lymphoid (drug effects, metabolism)
  • Protein Phosphatase 2 (antagonists & inhibitors, genetics, metabolism)
  • RNA, Messenger (genetics, metabolism)
  • Reverse Transcriptase Polymerase Chain Reaction
  • Signal Transduction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: